Coronavirus disease 2019 (COVID-19) can cause a wide range of cardiovascular diseases, including ST-segment elevation myocardial infarction (STEMI) and STEMI-mimickers (such as myocarditis, Takotsubo cardiomyopathy, among others). We performed a systematic review to summarize the clinical features, management, and outcomes of patients with COVID-19 who had ST-segment elevation. We searched electronic databases from inception to September 30, 2020 for studies that reported clinical data about COVID-19 patients with ST-segment elevation. Differences between patients with and without obstructive coronary artery disease (CAD) on coronary angiography were evaluated. Forty-two studies (35 case reports and seven case series) involving 161 patients were included. The mean age was 62.7 ± 13.6 years and 75% were men. The most frequent symptom was chest pain (78%). Eighty-three percent of patients had obstructive CAD. Patients with non-obstructive CAD had more diffuse ST-segment elevation (13% versus 1%, p = 0.03) and diffuse left ventricular wall-motion abnormality (23% versus 3%, p = 0.02) compared to obstructive CAD. In patients with previous coronary stent (n = 17), the 76% presented with stent thrombosis. In the majority of cases, the main reperfusion strategy was primary percutaneous coronary intervention instead of fibrinolysis. The in-hospital mortality was 30% without difference between patients with (30%) or without (31%) obstructive CAD. Our data suggest that a relatively high proportion of COVID-19 patients with ST-segment elevation had non-obstructive CAD. The prognosis was poor across groups. However, our findings are based on case reports and case series that should be confirmed in future studies. Supplementary Information The online version contains supplementary material available at 10.1007/s11239-021-02411-9.

Since the appearance of the new SARS-CoV-2 coronavirus (severe acute respiratory syndrome coronavirus 2) in December 2019, in Wuhan, China; patients were admitted with symptoms of pneumonia, named coronavirus disease 2019 (COVID-19); the virus spread, affecting different provinces in China and, after a few months, it is now present in more than 150 countries around the world. World Health Organization (WHO) has declared the novel coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020. 1 In Peru the first case was diagnosed on March 6th and from March 16th the government established a mandatory social isolation to prevent the COVID from further spreading in the country. COVID-19 has impacted and determined substantial changes in health systems in all countries; emergency, intensive, or intermediate care units carry the greatest burden, but several hospital wards have also been converted to COVID units, to face the growing wave of the disease. Many units of the different services, including cardiology, have redistributed their spaces and personnel dedicating them to become COVID-19 units. The resource allocation and priority setting measures, such as redirecting the personal protective equipment and hospital beds for patients with COVID-19 and the delay of elective cardiac

Systemize the evidence of pulmonary ultrasound (PU) use in diagnosis, monitorization or hospital discharge criteria for patients with COVID-19. Systematic review of evidence which utilized PU for diagnosis, monitorization, or as hospital discharge criteria for COVID-19 patients confirmed by RT-PCR between December 1st of 2019 and July 5th of 2020 compared with thoracic radiograph (TR), thoracic tomography (CT) and RT-PCR. Type of study, motives for PU, population, type of transducer and protocol, results of PU, and quantitative or qualitative correlation with TR and/or CT and/or RT-PCR were evaluated. Were evaluated 28 articles with 418 patients. Average age 50 years (SD 25.1 years), 395 adults and 23 children. 143 were women, 13 pregnant women. The most frequent result was diffuse, coalescent and confluent B-lines. The plural line was irregular, interrupted, or thickened. The presence of subpleural consolidation was noduliform, lobar, or multilobar. There was good qualitative correlation between TR and CT and a quantitative correlation with CT of r=0.65 (p<0.001). 44 patients were evaluated only with PU. PU is a useful tool for diagnosis, monitorization, and criteria for hospital discharge for patients with COVID-19.

We present the case of a 23-year-old man with cyanotic congenital cardiopathy and no prior surgical interventions, who presented to the hospital with intense occipital headache and left-sided weakness. Diagnostic imaging revealed the presence of a brain abscess directly attributable to his underlying cardiac condition. The patient received seven weeks of treatment, resulting in notable clinical and imaging improvement, leading to his discharge. Regrettably, due to a delayed diagnosis of complex cyanotic cardiopathy and a high surgical risk profile, the patient subsequently developed acute heart failure and tragically passed away at the age of 23.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Background: It has been proposed that transcatheter aortic valve replacement (TAVR) may be an option for patients with cancer and severe aortic stenosis. We assessed the association between previous or active cancer and clinical outcomes in TAVR patients.Methods: We searched four electronic databases from inception to March 05, 2021. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, myocardial infarction, stroke, acute kidney injury, pacemaker implantation, major bleeding, and vascular complications. All meta-analyses were performed using a random-effects model. Relative risks (RRs) and adjusted hazard ratios (aHRs) with their 95% confidence interval (95% CI) were pooled.Results: Thirteen cohort studies involving 255,840 patients were included. The time period for mortality ranged from inpatient to 10 years. Patients with active cancer had a higher risk of all-cause mortality using both crude (RR, 1.46; 95% CI, 1.13–1.88) and adjusted (aHR, 1.79; 95% CI, 1.43–2.25) estimates compared to non-cancer group. In contrast, the risk of cardiovascular mortality (RR, 1.26; 95% CI, 0.58–2.73), myocardial infarction (RR, 0.94; 95% CI, 0.34–2.57), stroke (RR, 0.90; 95% CI, 0.75–1.09), pacemaker implantation (RR, 0.87; 95% CI, 0.50–1.53), acute kidney injury (RR, 0.88; 95% CI, 0.74–1.04), major bleeding (RR, 1.15; 95% CI, 0.80–1.66), and vascular complications (RR, 0.96; 95% CI, 0.79–1.18) was similar between patients with or without cancer.Conclusion: Our review shows that TAVR patients with active cancer had an increased risk of all-cause mortality. No significant association with secondary outcomes was found.

No abstract